Acerus Pharma

2486 Dunwin Drive
Mississauga
Ontario
L5L 1J9
Canada

Tel: 416-679-0771

Website: http://www.aceruspharma.com/

Show jobs for this employer

129 articles with Acerus Pharma

  • Acerus Pharmaceuticals Corporation announced the voting results from its annual meeting of shareholders held on June 14, 2021 in Toronto, Ontario.

  • Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2021.

  • Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that it has entered into a three-year agreement with Amneal Pharmaceuticals Inc. (“Amneal”) to co-promote NATESTO in the U.S. Endocrinology segment, leveraging the company’s extensive relationships with Endocrinology healthcare providers. Amneal will promote NATEST

  • Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its first quarter 2021 financial and operating results on Thursday, May 13, 2021 before the market opens. The company will also host a conference call on Thursday, May 13, 2021 at 10:00 a.m. Eastern Time.

  • Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a US$15 million subordinated secured loan facility (the “ Loan Facility ”), which will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation Capital Inc.

  • Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a speciality pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement granting Maylen Farma (“Maylen”) the exclusive rights to market NATESTO ® in 20 countries across Europe, Central Asia, and the Middle East.

  • Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2020.

  • Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2020 financial and operating results on Thursday, March 11, 2021 before the market opens.

  • Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC (“SWK”) related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based

  • Acerus Pharmaceuticals Corporation (“ Acerus ” or the “ Company ”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the “ Rights Offering ”), Acerus issued 526,600,000 common shares of Acerus (“ Common Shares ”) under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,

  • Acerus Pharmaceuticals Corporation announced that the Company has received a waiver letter from SWK Funding LLC related to the required Revenue Covenant for the third quarter of fiscal 2020 in its existing credit facility.

  • Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Kevin Hickey has joined the Company as Senior Vice President, US Commercial. Mr. Hickey will become a member of Acerus’ Senior Leadership Team. “I am very pleased to announce that Kevin is joining the Company in this important new role as we strengthen our comme

  • Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Second Quarter Highlig

  • Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it will issue second quarter 2020 financial and operating results on Tuesday August 11, 2020 before the market opens. The Company will host an investor conference call that same day, August 11, at 10:00 a.m. Eastern Time, to discuss these results. To access the call live, please dial 416-406-0743 or 1-800-898-3989 and use

  • Acerus Announces Resumption of NATESTO ® Shipments Product En Route to United States and Taiwan TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a speciality pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced that production of new batches of NATESTO ® (testosterone nasal gel) is underway and shipments are already in transit to several key ma

  • Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Dr. Christopher Sorli, MD, PhD, FACE will join the Company as Chief Medical Officer, effective August 3, 2020, and will become a member of Acerus’ Senior Leadership Team. “I am very pleased to announce that Dr. Sorli is joining the Company in th

  • Acerus Announces Launch of NATESTO ® Specialty Sales Team in the United States Initially 22 in Size, Dedicated Staff to Target Urologists and Endocrinologists TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced the launch of a dedicated sales team to promote the Company’s key product,

  • Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing lice

  • Acerus Announces Significant Improvement in NATESTO ® Insurance Coverage in the United States NATESTO ® now covered as a Preferred Brand by leading national pharmacy benefits manager TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, as of July 1, 2020, Express Scripts, Inc., on

  • Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2020 (“Q1-2020). Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Q1-2020 Highlights Refinancing transactions provide $18 million of new capital to suppor